The primary objective of this proposal is to continue the strong participation of the USC ACTU in developmental therapeutics in HIV positive persons in the priority areas set by the ACTG Central Group Application. This will include participation in Phase I, Phase II, and Phase III studies in the areas of HIV infection, opportunistic infections, immune based therapy, wasting, clinical pharmacology, women's health, oncology, and neurologic complications. This overall objective can be subsumed under several specific aims. The USC ACTU will continue to provide high level expertise and leadership for the ACTG in critical areas of high priority research. With full funding, USC can provide as many as 120 subjects yearly, about 40% in trials of antiretroviral therapy, 40% in trials of HIV complications, and 20% in studies of immune based therapies. Most patients will be enrolled at the Los Angeles County+University of Southern California Medical Center. However, arrangements with Community Based Organizations for referral of patients will ensure the accessibility of ACTG protocols to a wide segment of the greater Los Angeles Community. Patients with the full range of immunodeficiency will be enrolled. These subjects will be of ethnic and gender diversity. Some 50% will belong to minority groups, 35-40% Hispanics, 15-20% Blacks, not Hispanic, and the remainder, White, not Hispanic or other. USC is a site for the Women's Interagency HIV Study, which will facilitate coenrollment of women from this natural history study into ACTG treatment trials. It is anticipated that 16-18% of the total enrollment at the USC ACTU will be women. The patients will be studied in state- of-the-art inpatient and outpatient facilities. An important component is a relocated, remodelled, and modernized General Clinical Research Center. The research at USC will be supported by strong existing laboratory programs in retrovirology, flow cytometry, applied pharmacokinetics, pharmacoanalysis, and viral carcinogenesis and cytokine biology. A separate laboratory area for specimen processing, logging, storage, packing, and shipment also exists. The HIV epidemic continues to spread. HIV and its complications will be important public health problems for decades to come. The USC ACTU will contribute to the rational management of this problem by the development of new treatment modalities to improve survival and quality of life. Coexisting educational programs at the USC ACTU site will also help disseminate knowledge about HIV disease and new treatment programs among health care professionals and the affected community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027673-13
Application #
2855973
Study Section
Special Emphasis Panel (SRC (82))
Program Officer
Batzold, Frederick
Project Start
1992-03-01
Project End
1999-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
13
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Sattler, Fred R; Chelliah, Daniel; Wu, Xingye et al. (2018) Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells. Pathog Immun 3:46-62
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Carlson, Jonathan M; Brumme, Chanson J; Martin, Eric et al. (2012) Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 86:13202-16
Kang, M; Cu-Uvin, S (2012) Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med 13:372-8
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Almeida, Coral-Ann M; Bronke, Corine; Roberts, Steven G et al. (2011) Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol 187:2502-13

Showing the most recent 10 out of 55 publications